BioCryst Reports Strong Q3 2026 Results Driven by Orladeyo Sales Growth
BioCryst Pharmaceuticals (BCRX) delivered robust third-quarter 2026 financial results, highlighted by a 13% year-over-year increase in total revenue to $180.3 million. The growth was primarily fueled by strong sales of Orladeyo, which generated $174.8 million in net revenue, representing a 20% comparable increase excluding European markets. The company demonstrated significant operational leverage, with non-GAAP net income more than doubling compared to the previous year. This profitability was supported by cost-saving measures from site closures and improved operating efficiencies. Consequently, BioCryst raised its full-year 2026 total revenue guidance to a range of $715 million to $730 million. Looking ahead, management is focusing on the transition to a new specialty pharmacy model and advancing its clinical pipeline. Top-line pivotal results for Navenibart are expected in Q3 2027, while initial data for BCX17725 targeting Netherton syndrome is anticipated by the end of 2026.
Tickers: $BCRX
Topics: Financial Guidance Operating Leverage Profitability Revenue Growth